X

Trial Profile

A phase II/III study assessing DNL-310 for Hunter syndrome

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 18 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tividenofusp alfa (Primary)
Indications Mucopolysaccharidosis II
Focus Proof of concept; Registrational; Therapeutic Use
Sponsors Denali Therapeutics Inc

Most Recent Events

10 Jan 2022 According to a Denali Therapeutics Inc media release, trial design of this study will be presented at the upcoming WORLDSymposium on lysosomal diseases, February 7-11, 2022.
10 Jan 2022 According to a Denali Therapeutics Inc media release, the company expect to begin patient dosing in 1H 2022.
08 Jan 2021 According to a Denali Therapeutics Inc media release, the company expect to initiate this trial in 1H 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com